Technetium-99m HM-PAO-labeled leukocytes in detection of inflammatory lesions: comparison with gallium-67 citrate

M Vorne1, I Soini, T Lantto

  • 1Department of Nuclear Medicine, Päijät-Häme Central Hospital, Lahti, Finland.

Insights

Technetium-99m labeled leukocytes offer a promising alternative to Gallium-67 citrate for diagnosing inflammatory and infectious diseases, showing higher accuracy and specificity. Further studies are needed for chronic osteomyelitis applications.

Area of Science:

  • Nuclear Medicine
  • Diagnostic Imaging

Background:

  • Leukocyte scintigraphy is crucial for diagnosing various diseases.
  • Gallium-67 citrate has been a standard but has limitations.

Purpose of the Study:

  • To compare the diagnostic efficacy of technetium-99m hexamethylpropyleneamine oxime (HM-PAO)-labeled leukocytes versus gallium-67 citrate.

Main Methods:

  • Forty-three patients with suspected benign, inflammatory, or infectious diseases underwent imaging using both radiopharmaceuticals.
  • Performance metrics including sensitivity, specificity, and accuracy were calculated for each agent.

Main Results:

  • Technetium-99m leukocytes demonstrated 92% sensitivity, 100% specificity, and 95% accuracy.
  • [67Ga]citrate showed 96% sensitivity, 63% specificity, and 81% accuracy.
  • Technetium-99m leukocytes provided faster results and lower radiation exposure.

Conclusions:

  • Technetium-99m labeled leukocytes are a superior diagnostic tool compared to [67Ga]citrate due to better accuracy, specificity, and patient safety.
  • The utility of technetium-99m leukocytes in chronic osteomyelitis requires additional investigation.